ATTO vs BEAM: fair value comparison
Attovia Therapeutics, Inc. and Beam Therapeutics Inc. · Updated 2026-10-19
ATTO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. BEAM has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, ATTO currently ranks higher by quality score.
| ATTO | BEAM | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $13.73 | $23.47 |
| 12-month range | $13.73–$22.22 | $20.60–$37.92 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #177 of 301 Healthcare | #179 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | — | Expanding |
| Revenue growth | — | Declining |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | — | Downtrend |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: ATTO fair value analysis · BEAM fair value analysis